Ticker Search:  Getting Started | Register | Videos | Newsletter | Partners | Login    

Basics
Blueprint Medicines Corporation
Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. Its drug candidates include avapritinib, BLU 554, BLU-782 and BLU-667.
IPO Date: May 1, 2015
Sector: Healthcare
Industry: Biotech
Market Cap: $8.35B
Activated in VL: True
Average Daily Range
Avg Daily Range: $1.46 | 2.35%
Avg Daily Range (30 D): $0.11 | 0.09%
Avg Daily Range (90 D): $1.31 | 1.42%
Institutional Daily Volume
Avg Daily Volume: .5M
Avg Daily Volume (30 D): 3.31M
Avg Daily Volume (90 D): 2.51M
Trade Size
Avg Trade Size (Sh.): 69
Avg Trade Size (Sh.) (30 D): 173
Avg Trade Size (Sh.) (90 D): 116
Institutional Trades
Total Inst.Trades: 6,873
Avg Inst. Trade: $3.91M
Avg Inst. Trade (30 D): $11.74M
Avg Inst. Trade (90 D): $8.66M
Avg Inst. Trade Volume: .05M
Avg Inst. Trades (Per Day): 3
Market Closing Trades
Avg Closing Trade: $6.56M
Avg Closing Trade (30 D): $87.45M
Avg Closing Trade (90 D): $36.6M
Avg Closing Volume: 80.91K
   
News
Jul 18, 2025 @ 5:00 AM
Press Release: Sanofi completes acquisition of Blu...
Source: Sanofi Press Release
Jul 18, 2025 @ 5:00 AM
Communiqué de presse : Sanofi finalise lâ€â„...
Source: Sanofi Press Release
Jul 17, 2025 @ 5:00 AM
Press Release: Sanofi announces extension of Bluep...
Source: Sanofi
Jul 17, 2025 @ 5:00 AM
Communiqué de presse : Sanofi annonce la prolon...
Source: Sanofi
Jul 14, 2025 @ 10:30 PM
$HAREHOLDER ALERT: The M&A Class Action Firm Annou...
Source: Juan Monteverde
Financials
  TTM Q1 2025 Q4 2024
Basic EPS $-2.48 $.01 $-.8
Diluted EPS $-2.48 $.01 $-.8
Revenue $ 562.12M $ 149.41M $ 146.37M
Gross Profit $ 542.35M $ 146.61M $ 138.92M
Net Income / Loss $ -155.73M $ .5M $ -49.96M
Operating Income / Loss $ -174.31M $ -41.09M $ -41.2M
Cost of Revenue $ 19.77M $ 2.8M $ 7.45M
Net Cash Flow $ 10.24M $ 19.79M $ 14.1M
PE Ratio